HCG (Human Chorionic Gonadotropin)
Also known as: HCG, hCG, Chorionic gonadotropin, Human chorionic gonadotrophin
3 notable studies · 3 references
TLDR
Human chorionic gonadotropin is an endogenous pregnancy hormone and clinically established LH-receptor agonist that directly stimulates gonadal steroid production and is used in reproductive medicine for indications including selected forms of male hypogonadism and infertility and female ovulation induction, although evidence strength varies across specific fertility applications.
Research Supports
- Studied for stimulating testosterone production via LH-receptor activation in men
- Investigated for supporting spermatogenesis and male fertility
- Studied in hypogonadotropic hypogonadism management
- Used in reproductive medicine for ovulation induction and assisted reproduction
- Investigated for preserving testicular function during exogenous testosterone use
Observations Reported in Research
- 2025 systematic review (Shoaib et al.): 7 trials, 926 men, mixed results across infertility subgroups
- Some subgroups showed improved sperm or pregnancy-related outcomes; others showed limited evidence
- Reviews describe HCG as an established option for secondary hypogonadism, particularly for fertility
- Clinical literature distinguishes HCG's LH-like activity from the FSH activity it lacks
These are brief summaries of what the referenced research examined or reported — not conclusions about safety or effectiveness, and not medical advice. See Notable Studies and Sources & References below for the full context and citations.
At a Glance
Classification: Glycoprotein hormone; luteinizing-hormone receptor agonist; gonadotropin
Human chorionic gonadotropin is a naturally occurring glycoprotein hormone produced primarily by placental trophoblast cells during pregnancy. HCG is not a conventional short peptide. It's a much larger heterodimeric glycoprotein hormone consisting of alpha and beta subunits. Its structural similarity to luteinizing hormone allows HCG to activate the same receptor: LHCGR — luteinizing hormone/choriogonadotropin receptor. That produces two particularly important effects: In males, HCG → LH receptor on Leydig cells → testosterone. In females, HCG → LH receptor → ovulatory/luteal signaling. Unlike most compounds we've covered recently, HCG has decades of clinical use and extensive human evidence.
What Is HCG (Human Chorionic Gonadotropin)?
HCG consists of two subunits: α-subunit and β-subunit. Its alpha subunit is closely related to those found in LH, FSH, and TSH. The beta subunit gives HCG much of its biological specificity. During pregnancy, placental HCG maintains the corpus luteum, supporting progesterone production during early gestation until placental steroid production becomes sufficient. Pharmacologically, its similarity to LH allows it to activate LHCGR. That's why it can be used to stimulate gonadal function.
What Are Researchers Studying?
Male testosterone production
In males, HCG binds LH receptors on Leydig cells. That stimulates endogenous testosterone synthesis. This is direct gonadal stimulation: HCG → LHCGR → testosterone. It does not require the pituitary to release LH first. That's the key difference from gonadorelin. Clinical literature supports HCG as an established option in selected men with secondary/hypogonadotropic hypogonadism.
Spermatogenesis and male fertility
HCG's role in fertility is particularly important because endogenous intratesticular testosterone is necessary for normal spermatogenesis. External testosterone can suppress: GnRH → LH/FSH → intratesticular testosterone and consequently suppress sperm production. HCG can replace some of the missing LH-like stimulation at the testes. Clinical literature therefore examines HCG for: Hypogonadotropic hypogonadism; Induction of spermatogenesis; Fertility preservation; Recovery of spermatogenesis after suppression. But HCG isn't identical to the entire pituitary reproductive signal. It provides LH-like activity—not FSH activity. Some infertility situations therefore require additional FSH stimulation.
Hypogonadotropic hypogonadism
Men with inadequate hypothalamic/pituitary gonadotropin signaling may have: Low LH; Low FSH; Low testosterone; Impaired sperm production. HCG can bypass deficient LH secretion and directly stimulate testicular LH receptors. Reviews describe HCG as an important treatment option for secondary hypogonadism, particularly where fertility matters.
Ovulation and assisted reproduction
HCG's LH-like activity can reproduce aspects of the natural LH surge. Consequently, HCG has long been used in reproductive medicine to trigger final follicular maturation and ovulation. This has applications in: Ovulation induction; Assisted reproductive technology; IVF. This is established clinical reproductive endocrinology, not speculative research-compound use.
Pregnancy biology
Endogenous HCG is one of the defining hormones of early pregnancy. Its physiological functions include maintaining the corpus luteum and supporting progesterone production. Because HCG concentrations rise rapidly after implantation, it also became the molecular basis of most pregnancy tests. That diagnostic role is entirely separate from administering HCG as a drug.
Fertility during testosterone exposure
One particularly popular research-market discussion involves HCG alongside testosterone. The biological rationale is real: Exogenous testosterone suppresses endogenous LH. Lower LH reduces Leydig-cell stimulation and intratesticular testosterone. HCG can activate those receptors despite suppressed pituitary LH. Human literature supports HCG's ability to help maintain or restore aspects of testicular function and spermatogenesis in appropriate settings. But that doesn't mean every testosterone/HCG regimen circulating online is evidence-based. The therapeutic strategy and a particular internet protocol are two separate questions.
How Does It Work?
HCG binds LHCGR → activates G-protein signaling → increases intracellular cAMP → stimulates steroidogenic pathways. Male: Leydig cell → cholesterol-derived steroidogenesis → testosterone. Female: ovarian LH receptor → final follicular maturation / ovulatory signaling → corpus-luteum formation and steroid production. HCG therefore acts much farther downstream than gonadorelin.
What Does the Research Show?
Human research
Human evidence is extensive. This includes decades of experience involving: Male hypogonadotropic hypogonadism; Testosterone production; Spermatogenesis; Male infertility; Ovulation induction; Assisted reproduction. However, evidence varies considerably by indication. A 2025 systematic review of randomized trials in male infertility included seven trials and 926 men. Some populations showed improvements in pregnancy-related outcomes, while evidence in others remained limited or uncertain. That's useful nuance: HCG is an established hormone drug. That doesn't mean it has equally strong evidence for every proposed use.
Animal research
HCG has been used extensively in reproductive animal research. But because human reproductive pharmacology is already well established, animal efficacy findings are much less important for this Aminodex profile than they are for experimental compounds.
In-vitro research
Cellular research has extensively characterized: LHCGR binding; cAMP signaling; Leydig-cell steroidogenesis; Ovarian steroidogenesis; Receptor internalization; HCG/LH signaling differences. Interestingly, LH and HCG activate the same receptor but aren't necessarily biologically identical in every signaling dimension. That remains an active area of receptor pharmacology.
Notable Studies
Human Chorionic Gonadotropin Treatment: A Viable Option for Management of Secondary Hypogonadism and Male Infertility
humanThe review evaluated HCG in men with low testosterone and infertility. The literature supports HCG's ability to stimulate endogenous testosterone and sperm production through LH-receptor activation, making it particularly relevant when preservation of fertility is important.
Limitations: Review rather than a single large randomized trial. Evidence strength differs by patient population and treatment objective.
View publication →Indications for the Use of Human Chorionic Gonadotropic Hormone for the Management of Infertility in Hypogonadal Men
humanThe authors reviewed HCG use in hypogonadal men, including maintenance or restoration of spermatogenesis where endogenous gonadotropin signaling has been suppressed. The paper highlights the fundamental difference between exogenous testosterone—which can suppress spermatogenesis—and HCG, which stimulates testicular LH receptors.
Limitations: Review-level evidence; clinical outcomes and appropriate use depend on the underlying cause of hypogonadism and fertility status.
View publication →Use of Human Chorionic Gonadotropin (HCG) or HCG-Combined Treatments in Male Infertility: A Systematic Review
humanSeven randomized trials involving 926 men were included. Some subgroups demonstrated improvements in sperm or pregnancy-related outcomes, but results varied substantially by underlying infertility diagnosis and treatment combination. The authors concluded that evidence remained limited for broad HCG use across male infertility populations.
Limitations: Heterogeneous populations and interventions, limited reporting of live births and adverse events, and wide confidence intervals for some outcomes.
View publication →What We Still Don't Know
HCG itself is extremely well characterized, but uncertainty remains around some popular contemporary uses: Optimal fertility-preservation strategies during exogenous testosterone therapy; Which men need HCG alone versus HCG + FSH; Long-term outcomes of various off-label regimens; Comparative outcomes versus alternative fertility treatments; Which infertility subgroups derive meaningful pregnancy/live-birth benefit; Long-term outcomes of research-market use outside medical supervision; Quality and identity of non-pharmaceutical HCG products. The uncertainty should not be confused with the experimental compounds we've covered. HCG isn't a mysterious new research chemical. It's an established human hormone with established pharmacology and clinical uses.
Related Compounds
Recent publications
Latest titles from PubMed, not reviewed by Aminodex. Not an endorsement. See all on PubMed ↗
Take the HCG (Human Chorionic Gonadotropin) research with you.
Get the Aminodex HCG (Human Chorionic Gonadotropin) Brief—a concise summary of the research, notable studies, evidence types, limitations, and references.
One-time email. We do not add you to any mailing list.
Sources & References
- Human Chorionic Gonadotropin Treatment: A Viable Option for Management of Secondary Hypogonadism and Male Infertility. 2020.
- Lee JA, Ramasamy R. Indications for the Use of Human Chorionic Gonadotropic Hormone for the Management of Infertility in Hypogonadal Men. 2018.
- Shoaib H, Duffy J, Ahmed K. Use of Human Chorionic Gonadotropin (HCG) or HCG-Combined Treatments in Male Infertility: A Systematic Review. 2025.
Supplier Listings
Disclosure: The owner of Aminodex operates the supplier(s) marked below. These listings are promotion for businesses we own, not independent recommendations. Read our disclosures.